LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...

Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by ...

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

Data shared by Schneider showed that 45% of those originally assigned to the Eylea HD groups had completed dosing intervals of 20 weeks or more. At the end of the 156-week trial, 28% had an assigned ...

Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...